tradingkey.logo

Alterity Reports Positive Phase 2 Data for ATH434 in MSA, Shows Clinical Benefit and Biomarker Impact

ReutersJul 28, 2025 11:36 AM

- Alterity Therapeutics Ltd ATH.AX:

  • ALTERITY THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM OPEN-LABEL PHASE 2 CLINICAL TRIAL OF ATH434 IN MULTIPLE SYSTEM ATROPHY

  • ALTERITY THERAPEUTICS LTD - ATH434 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE

  • ALTERITY THERAPEUTICS LTD - NO SERIOUS ADVERSE EVENTS REPORTED FOR ATH434

  • ALTERITY THERAPEUTICS LTD - ATH434 SHOWS CLINICAL BENEFIT AND STABILIZES SYMPTOMS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI